Drugs / IPH2101
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01217203 | Sep 2010 → Dec 2013 | plasma cell myeloma | Innate Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00552396 | May 2007 → Jan 2011 | plasma cell myeloma | Innate Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01256073 | Feb 2007 → Jul 2013 | acute myeloid leukemia | Innate Pharma | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01248455 | Nov 2010 → May 2014 | smoldering plasma cell myeloma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01222286 | Sep 2010 → Jul 2012 | smoldering plasma cell myeloma | Innate Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00999830 | Sep 2009 → Jun 2012 | plasma cell myeloma | Innate Pharma | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-10-18 | Innate Pharma | Results Results of IPH2101 Phase I trial in AML published in BLOOD innate-pharma.com ↗
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the results of the Phase I trial of IPH2101 (hybridoma anti-KIR antibody) in elderly patients with Acute Myeloid Leukemia in first complete remission were published online in the journal Blood. |
All press releases naming this drug 9 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPH2101 | “Anti-KIR (IPH2101) is a monoclonal antibody that facilitates NK cell mediated killing of myeloma cells by blocking inhibitory receptors (KIR) on NK cells.” NCT01248455 ↗5“A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.” PMID 23033266 ↗ Oct 2012 |
| Known as | 1-7F9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109498 ↗ |
| Known as | Anti-KIR | “Anti-KIR (IPH2101) is a monoclonal antibody that facilitates NK cell mediated killing of myeloma cells by blocking inhibitory receptors (KIR) on NK cells.” NCT01248455 ↗ |
| Known as | IHP-2101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109498 ↗ |
| Action | Activate | “which activates the body's own cells to kill tumor cells” NCT00552396 ↗ |
| Action | Inhibit | “Killer cell immunoglobulin-like receptor 2DL2 inhibitor” CHEMBL2109498 ↗2“Killer cell immunoglobulin-like receptor 2DL3 inhibitor” CHEMBL2109498 ↗ “Killer cell immunoglobulin-like receptor 2DL1 inhibitor” CHEMBL2109498 ↗ |
| Modality | Monoclonal antibody | “human monoclonal antibody” NCT00552396 ↗ |
| Route | Intravenous | “IPH2101 was administered intravenously every 28 days” PMID 23033266 ↗ Oct 2012 |
| Target | KIR2DL1 | “Killer cell immunoglobulin-like receptor 2DL1 inhibitor” CHEMBL2109498 ↗ |
| Target | KIR2DL2 | “Killer cell immunoglobulin-like receptor 2DL2 inhibitor” CHEMBL2109498 ↗ |
| Target | KIR2DL3 | “Killer cell immunoglobulin-like receptor 2DL3 inhibitor” CHEMBL2109498 ↗ |